Wall Street analysts expect NewLink Genetics Corp (NASDAQ:NLNK) to announce earnings per share of ($0.58) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for NewLink Genetics’ earnings, with the lowest EPS estimate coming in at ($0.74) and the highest estimate coming in at ($0.44). NewLink Genetics reported earnings per share of ($0.57) in the same quarter last year, which would suggest a negative year over year growth rate of 1.8%. The company is expected to announce its next earnings results on Friday, July 27th.
According to Zacks, analysts expect that NewLink Genetics will report full-year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.55) to ($1.67). For the next fiscal year, analysts forecast that the business will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.72) to $0.06. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for NewLink Genetics.
NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. NewLink Genetics had a negative return on equity of 55.64% and a negative net margin of 193.44%. The business had revenue of $9.90 million during the quarter, compared to analyst estimates of $5.78 million.
Several equities analysts have recently commented on the company. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics and gave the company a “buy” rating in a research report on Friday, March 2nd. Robert W. Baird downgraded NewLink Genetics from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $22.00 to $5.00 in a research report on Monday, April 9th. Jefferies Financial Group downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Friday, April 6th. Bank of America downgraded NewLink Genetics from a “buy” rating to a “neutral” rating in a research report on Friday, April 6th. Finally, ValuEngine downgraded NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the stock. NewLink Genetics currently has an average rating of “Hold” and an average price target of $10.50.
NASDAQ:NLNK traded up $0.06 during mid-day trading on Friday, hitting $4.97. 2,950 shares of the company traded hands, compared to its average volume of 600,837. NewLink Genetics has a one year low of $3.75 and a one year high of $19.30. The firm has a market capitalization of $188.80 million, a PE ratio of -2.14 and a beta of 1.25.
Several institutional investors have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of NewLink Genetics in the fourth quarter worth about $118,000. Raymond James & Associates purchased a new stake in shares of NewLink Genetics in the fourth quarter worth about $240,000. Two Sigma Advisers LP purchased a new stake in shares of NewLink Genetics in the fourth quarter worth about $269,000. Two Sigma Investments LP purchased a new stake in shares of NewLink Genetics in the fourth quarter worth about $312,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of NewLink Genetics in the fourth quarter worth about $336,000. Institutional investors and hedge funds own 53.03% of the company’s stock.
About NewLink Genetics
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Get a free copy of the Zacks research report on NewLink Genetics (NLNK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.